Home  »  Stock   »  HALO: Riding the Market Waves of Growth and Declin...

HALO: Riding the Market Waves of Growth and Decline in 2023

The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. Year to date metric has recorded a loss of -27.89%.However, over the last six months, we can see a stronger performance of -2.31%. Over the last 30 days, the price of HALO has leaped by -6.45%. And in the last five days, it has surged by 0.02%.

At present, Halozyme Therapeutics Inc. (HALO) has a stock price of $41.03. In the previous session, the stock saw a rise, peaking at $41.50 after an opening price of $38.82. The day’s lowest price was $38.82, and it closed at $38.92.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Halozyme Therapeutics Inc. experienced a rather shaky stock market performance. The highest value in the past year was recorded at $59.46 on 12/02/22 and the lowest value was $29.85 on 05/09/23.

52-week price history of HALO Stock

Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Halozyme Therapeutics Inc.’s current trading price is -31.00% away from its 52-week high, while its distance from the 52-week low is 37.45%. The stock’s price range during this period has varied between$29.85 and $59.46. The Halozyme Therapeutics Inc.’s shares, which operate in the Healthcare, saw a trading volume of around 1.3 million for the day, a figure considerably higher than their average daily volume of 1.04 million over last three months.

Market Capitalization vs. Financial Performance: A Comparative Study

Halozyme Therapeutics Inc. (HALO) has experienced a quarterly rise of 21.21% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.50B and boasts a workforce of 393 employees.

Halozyme Therapeutics Inc.: Analysts’ Ratings Unveiled

As of right now, 7 analysts are rating Halozyme Therapeutics Inc. as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts are recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 analyst is rating the stock as SELL.

Combining Moving Average and Trading Volume Data for Better Market Insight

Based on Barchart.com data, the company’s moving average over the 100-day period was 37.50, with a change in price of +7.13. Similarly, Halozyme Therapeutics Inc. recorded 1,084,189 in trading volume during the last 100 days, posting a change of +21.03%.

HALO’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look

The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for HALO stands at 9.91. Similarly, the long-term debt-to-equity ratio is also 9.91.

HALO Stock Stochastic Average

Halozyme Therapeutics Inc.’s raw stochastic average for the past 50 days is presently 57.27%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 55.47%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 26.26% and 12.39%, respectively.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts